Isomorphic Labs raises $2.1B funding

Isomorphic Labs said on May 12 that it had raised $2.1 billion in a Series B round, giving one of the highest-profile AI drug-discovery companies a fresh pool of capital to expand its computing platform, hire staff and advance drug programs. The London-based company said Thrive Capital led the round, with existing backers Alphabet and GV joining new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. (isomorphiclabs.com) The financing adds to the $600 million external round that Isomorphic Labs announced on March 31, 2025, also led by Thrive Capital with participation from GV and Alphabet. The company, founded in 2021 out of DeepMind, has positioned itself as a specialist in applying frontier AI to molecular modeling and drug design. (isomorphiclabs.com) ### Why is this round bigger than the earlier Isomorphic Labs financing? The $2.1 billion Series B is more than three times the size of the $600 million round Isomorphic Labs disclosed in March 2025. In its May 12 statement, the company said the new capital would be used to power its AI drug-design engine, scale the business globally and progress its drug-candidate pipeline. (isomorphiclabs.com) Thrive Capital appeared in both financings, but the new round broadened the investor base. The May 12 announcement named MGX, Temasek, CapitalG and the UK Sovereign AI Fund as new participants alongside Alphabet and GV. (isomorphiclabs.com) ### What exactly is Isomorphic Labs building with the money? Isomorphic Labs says its core platform is the Isomorphic Labs Drug Design Engine, or IsoDDE, a unified computational system for drug design. In a technical overview published this year, the company said the system extends beyond AlphaFold 3 by improving protein-ligand structure prediction, estimating binding affinity and identifying binding pockets from amino-acid sequence data. (isomorphiclabs.com) The company’s technology page says its models are designed to run large volumes of in-silico experiments across large GPU fleets using a curated internal “dataverse” of life-science data. That helps explain why new funding is likely to be directed not only to research teams but also to cloud and computing infrastructure, even though the May 12 release framed the spending more broadly around platform development and scaling. (isomorphiclabs.com) ### How does AlphaFold fit into the story? Google DeepMind and Isomorphic Labs introduced AlphaFold 3 in May 2024 as a model for predicting the structure and interactions of proteins, DNA, RNA and ligands. Google said at the time that Isomorphic Labs was already using that work with pharmaceutical companies on real-world drug-design problems. (isomorphiclabs.com) Demis Hassabis, who founded Isomorphic Labs and also leads Google DeepMind, has tied the company’s mission directly to that lineage. On Isomorphic Labs’ website, Hassabis says there is “no more important application for AI than helping to improve human health.” (isomorphiclabs.com) ### Which drugmakers are already working with Isomorphic Labs? Isomorphic Labs says it has active partnerships with Novartis, Eli Lilly and Johnson & Johnson. Its partnerships page says the Novartis collaboration, first announced in January 2024 and expanded in February 2025, covers small-molecule discovery programs, while the Johnson & Johnson collaboration was announced in January 2026. (blog.google) The company has not publicly detailed the full list of targets under those programs. But its public materials say the collaborations span multiple therapeutic areas and modalities, and the May 12 financing announcement said the company intends to use the new capital to move its own candidate pipeline forward. (isomorphiclabs.com) ### What happens next after the funding announcement? May 12 is the key date in the company’s formal announcement, not May 20 as some social posts suggested. The next visible milestones are likely to come through additional partnership updates, pipeline disclosures or technical publications tied to IsoDDE, which Isomorphic Labs has been using to showcase benchmark results and platform capabilities. (isomorphiclabs.com) The company’s news page lists the Series B announcement alongside recent items including its January 20, 2026 Johnson & Johnson collaboration and earlier financing and hiring updates. That page, together with future investor and partnership materials from the named backers, is the clearest place to track the next step. (isomorphiclabs.com 1) (isomorphiclabs.com 2)